US Patent 7618631 Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs
Patent 7618631 was granted and assigned to Genentech on November, 2009 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
June 16, 2005
Date of Patent
November 17, 2009
Patent Application Number
11154465
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 7618631 Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
